Background: For reimbursement purposes of pimecrolimus cream 1%, the Belgian authorities asked to document its consumption, its topical corticosteroid-sparing effect and quality of life within the routine clinical practice. Objectives: We aimed to address the 3 queries of the Belgian authorities. Methods: An open-label, observational, multicentre, 1-year study under drug prescription was performed. Results: A total of 416 consecutive patients were enrolled in 49 centres. The mean annual amount of prescribed pimecrolimuscream 1% per patient was 120.8 g (SD = 117.0), with an estimated consumption of 104.4 g (SD = 117.6). The median annual amount prescribed was 90.0 g [interquartile range (IQR) = 45–150] and the estimated consumption 63.6 g (IQR = 32.4–132). Topical corticosteroids had been used before the study in 81.7% of the population. With pimecrolimus cream 1% during the study, 83.3% of the previous corticosteroid users stated less topical corticosteroid use than before and 36% of them did not apply topical corticosteroids at all during the study. The mean improvements compared to baseline in Parents’ Index Quality of Life-Atopic Dermatitis and Quality of Life Index-Atopic Dermatitis scores were 34.5% (SD = 84.3) and 31.2% (SD = 70.8), respectively. The median improvements were 50.0% (IQR = 12.5–85.7%) and 46.4% (IQR = 0.0–85.0%), respectively. Conclusions: In routine practice the consumption of pimecrolimus cream 1% is relatively low, with corticosteroid-sparing effect, improvement in quality of life and good tolerability.

1.
McKenna SP, Whalley D, Dewar AL, Erdman RAM, Kohlmann T, Niero M, Baro E, Cook SA, Crickx B, Frech F, van Assche D: International development of the Parents’ Index of Quality of Life in Atopic Dermatitis (PIQoL-AD). Qual Life Res 2005;14:231–241.
2.
Whalley D, McKenna SP, Dawar AL, Erdman RA, Kohlmann T, Niero M, Cook SA, Crickx B, Herdman MJ, Frech F, van Assche D: A new instrument for assessing quality of life in atopic dermatitis: international development of the Quality of Life Index for Atopic Dermatitis (QoLIAD). Br J Dermatol 2004;150:274–283.
3.
Cleemput I: Validation of two disease-specific quality of life questionnaires for atopic dermatitis in Belgium. Final report. Meise, Health Economics Disease Management (HEDM), January 13, 2004.
4.
Wahn U, Bos JD, Goodfield M, Caputo R, Papp K, Manjra A, Dobozy A, Paul C, Molloy S, Hultsch T, Graeber M, Cherill R, de Prost Y: Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002;110:1–8.
5.
Meurer M, Fölster-Holst R, Wozel G, Weidinger G, Jünger M, Bräutigam M: Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatology 2002;205:271–277.
6.
Lübbe J, Frielander SF, Cribier B, Morren MA, Garcia-Diez A, Gelmetti C, Hofmann H, Houwing RH, Kownacki S, Langley RGB, Virtanen M, Wolff K, McGeown C, Abrams B, Schneider D: Safety, efficacy, and dosage of 1% pimecrolimus cream for the treatment of atopic dermatitis in daily practice. Am J Clin Dermatol 2006;7:121–131.
7.
Simon D, Lübbe J, Wüthrich B, Wiesner A, Weber MM, Laffitte E, Anliker MD, Schöni MH, Braathen LR, Schmid-Grendelmeier P, Gilgen Bobalj N, Scheider D: Benefits from the use of a pimecrolimus-based treatment in the management of atopic dermatitis in clinical practice. Dermatology 2006;213:313–318.
8.
Krejci-Manwaring J, Tusa MG, Carroll C, Camacho F, Kaur M, Carr D, Fleischer AB, Balkrishnan R, Feldman SR: Stealth monitoring of adherence to topical medication: adherence is very poor in children with atopic dermatitis. J Am Acad Dermatol 2007;56:211–216.
9.
Zuberbier T, Heinzerling L, Bieber T, Schauer U, Klebs S, Bräutigam M: Steroid-sparing effect of pimecrolimus cream 1% in children with severe atopic dermatitis. Dermatology 2007;215:325–330.
10.
Meurer M, Fartasch M, Albrecht G, Vogt T, Worm M, Ruzicka T, Altmeyer PJ, Schneider D, Weidinger G, Bräutigam M: Long-term efficacy and safety of pimecrolimus cream 1% in adults with moderate atopic dermatitis. Dermatology 2004;208:365–372.
11.
Niren N, Chang J, Wang Q, Sung J: Impact of atopic dermatitis treatment on parent’s quality of life: results from findings in atopic children with eczema (FACE) study (poster abstract P719). J Am Acad Dermatol 2005;52:71.
12.
McKenna S, Matheson R, Gulliver W, Abrams B: Impact of pimecrolimus cream 1% on quality of life in atopic dermatitis: results from the 6-month, naturalistic NOBEL study (poster abstract P720). J Am Acad Dermatol 2005;52:71.
13.
Margolis DJ, Hoffstad O, Bilker W: Lack of association between exposure to topical calcineurin inhibitors and skin cancer in adults. Dermatology 2007;214:289–295.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.